ALN-ANG3 + Evinacumab for Diabetic Kidney Disease
(ANCHOR-POC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease.
The aim of the study is to see how safe and effective the study drugs are.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
Who Is on the Research Team?
Clinical Trial Management
Principal Investigator
Regeneron Pharmaceuticals
Are You a Good Fit for This Trial?
Adults with type 2 diabetes and diabetic kidney disease can join this trial. They must be managing their diabetes through medication or lifestyle changes, have an HbA1c level between 6.5 to 10%, eGFR of 30 to 90 mL/min/1.73 m^2, and a specific range of albumin in their urine (UACR of 500 to 5000 mg/g).Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- ALN-ANG3
- Evinacumab
Trial Overview
The trial is testing the safety and effectiveness of two experimental drugs: ALN-ANG3 and evinacumab for treating diabetic kidney disease. Participants will receive either one of these drugs or a placebo while researchers monitor drug levels in the blood and observe outcomes.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
Regeneron Pharmaceuticals
Lead Sponsor
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer since 1988
MD and PhD in Medicine
George Yancopoulos
Regeneron Pharmaceuticals
Chief Medical Officer since 1997
MD from Harvard Medical School
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.